Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02239666 · ClinicalTrials.gov registry record

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

A clinical trial, sponsored by AstraZeneca.

Completed
Registry status
899
Enrollment target

NCT02239666 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 899 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02239666 has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
899 participants
Enrollment target

Study Summary

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Interventions

  • OTHER NIS

Trial Details

FieldValue
Enrollment Target 899 participants
Start Date 2014-03-01
Est. Completion 2017-01-05

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT02239666

The ClinicalTrials.gov registry entry for NCT02239666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NIS is the first listed.

NCT02239666 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02239666 about?

NCT02239666 is a clinical study titled "Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis". To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

What is the current status of trial NCT02239666?

This trial is currently completed. The enrollment target is 899 participants. The study started on 2014-03-01. Estimated completion is 2017-01-05.

What interventions are being tested in trial NCT02239666?

The interventions under investigation include: NIS (OTHER).

Who is sponsoring clinical trial NCT02239666?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.